Formazione >> Conferenze e Workshop >> Best Practices for Extractables & Leachables Studies in the Pharmaceutical & Medical Devices Industry

Best Practices for Extractables & Leachables Studies in the Pharmaceutical & Medical Devices Industry

Sidebar Image

Date:                     March 14th 2019 (9:30-17:30)

Location:               Leonardo City Tower Hotel, Tel Aviv (Israel)

Registration fee:   Early bird registration fee (Valid until 28.02.2019): 790 NIS
                               Full registration fee: 990 NIS

Registration:         Online registration   

                              > Download Brochure                 

Introduction

The importance of extractables and leachables testing in the pharmaceutical and medical device industry has grown significantly in the last few years driven by a substantial growth in global regulatory requirements. A drug product container-closure system should not release chemicals that can accumulate in the drug product in quantities sufficient to present a risk of toxicity, or affect its stability or efficacy. Extractables and leachables testing is also an important component in establishing the biocompatibility of a medical device as required by ISO 10993.

Substances may migrate from different materials and patients may be exposed through different routes of administration. During the drug development process and medical devices study design it is important to evaluate the potential for various chemicals to migrate. Risk assessment of product configuration or manufacturing chain should be performed as well as a proper toxicological evaluation.

Regulatory agencies require extractables and leachables testing to identify any risks of product adulteration. FDA and international regulators are also placing an increasing emphasis on characterizing the chemical components of devices, including colorants and polymers. Failure to demonstrate material safety could result in failure to receive regulatory approval for a product from authorities
such as FDA and EMA. Consequently, extractables and leachables studies are now a crucial component of product release.

This conference will provide a wide and comprehensive overview of critical aspects, technical considerations and strategies for establishing an extractables study design that provides meaningful data, including the advantages and disadvantages of various analytical techniques for the pharmaceutical and medical device industry. The normative approach according to USP, ISO 10993-1 and
ISO/DIS 10993-18) will be discussed in detail.

By attending, participants will gain valuable insight from our first class expert’s comprehensive expertise on how to conduct risk assessment and toxicological evaluation recommending testing options that are up to current industry and regulatory standards and expectations.

Target audience

This course offers a rewarding experience and is particularly relevant to the following key figures:
R&D Manager, CQ Manager, QA Manager, Regulatory Manager, Production Manager, Packaging Manager, CMC manager
and Validation Manager.

Conference Agenda

9:00 - 9:30: Registration

9:30 - 10:00: Introduction and general overview:
                    • Extractables and leachables definition
                    • The difference between extractables and leachables
                    • Guidelines regulatory requirements (USP<1663> <1664>; ISO 10993-1; ISO/DIS 10993-18)
                     Simone Carrara; Chiara Picotti

10:00 - 11:15: Extractables studies:
                      • When and how to set up an extractable study
                      • Critical evaluation of the packaging system, process components and drug properties (Risk Based Approach)
                      • Setting up an extractables study (Design of Experiment):
                        - Selection of extraction conditions
                        - Selection of extractive solvents
                        - Selection of extractive techniques (HS/GC/MS-GC/MS HPLC/MS/UV-ICP/OES-ICP/MS-Ion Chromatography)
                        - Definition of screening methods and minimum sensitivity request
                      • Specific case study
                       Simone Carrara

11:15 - 11:30: Coffee break

11:30 - 12:30: Peculiar feature of extractables and leachables for medical devices
                       Chiara Picotti

12:30 - 13:00: BPOG
                       Simone Carrara

14:00 - 15:45: Toxicological evaluation: Integrated approach:
                       • Maximum Daily Intake (MDI)
                       • Threshold of Toxicological Concern (TTC)
                       • Different approaches to the interpretation of data of known and unknown compounds
                       • Tolerable Intake (TI)/Tolerable Exposure (TE)
                       • NOAEL-LOAEL: Definition and selection criteria
                       • Uncertainty factors
                       • In silico predictions
                       • Cramer scheme, ToxTree Benigni/Bossa
                       • Specific case study
                        Chiara Picotti

15:45 - 16:00: Coffee break

16:00 - 16:30: Leachables studies:
                      • When and how to set up a leachablee study
                      • The approach on known and unknown extractables
                      • Targeted & non-targeted leachable screening
                      • Method development and validation
                      • Leachables studies stability plan
                      • Specific case study
                       Simone Carrara

16:30 - 17:15: Final case study step by step (prefilled syringe and administration set):
                      • Extractables studies
                      • Toxicological approach
                      • Leachables studies
                       Simone Carrara; Chiara Picotti

17:15 - 17:30 Final questions and answers

Top Speakers

Chiara Picotti
With a degree in Biomedical Engineering she gained strong experience in the biological evaluation of medical devices field as senior consultant and Toxicological and Biological Evaluation Group Leader in Eurofins Medical Device Testing Italy. She manages a dedicated team for the calculation of the Permitted Daily Exposure in shared Facility and toxicological evaluations of extractables & leachables studies on medical devices, pharmaceutical packaging and process components.

Simone Carrara
Simone holds a Biotechnology degree from the University of Milan and has a vast experience as bio-analytical researcher through LC/MS method development for Pharmacokinetics analysis and ADMET profiling. In his previous role as Project Leader he has successfully managed different projects in a wide range of areas including analytical method development and validation with LC/MS-GC/MS, and drug product impurities characterization. For the last 5 years he has been focusing on extractables & leachables studies to support drug-manufacturing companies to fulfill regulatory requirements. He is currently Extractables & Leachables and impurity characterization
Laboratory Manager in Eurofins BioPharma Product Testing Italy.

Organisation and Contact

Eurofins BPT & MDT Italy
Via Bruno Buozzi, 2
20090 - Vimodrone (Italy)
e-mail: FormazioneFarma@eurofins.com
website: www.eurofins.com/Medical-Device
website: www.eurofins.com/BPT

Edu-Med
9 Hagilad St. Ramat Gan
P.O Box 11530, ISRAEL
e-mail: office@edu-med.info

All Items

The importance of extractables and leachables testing in the pharmaceutical and medical device industry has grown significantly in the last few years driven by a substantial growth in global regulatory requirements. A drug product container-closure system should not release chemicals that can accumulate in the drug product in quantities sufficient to present a risk of toxicity, or affect its stability or efficacy. Extractables and leachables testing is also an important component in establishing the biocompatibility of a medical device as required by ISO 10993.

Substances may migrate from different materials and patients may be exposed through different routes of administration. During the drug development process and medical devices study design it is important to evaluate the potential for various chemicals to migrate. Risk assessment of product configuration or manufacturing chain should be performed as well as a proper toxicological evaluation.

Regulatory agencies require extractables and leachables testing to identify any risks of product adulteration. FDA and international regulators are also placing an increasing emphasis on characterizing the chemical components of devices, including colorants and polymers. Failure to demonstrate material safety could result in failure to receive regulatory approval for a product from authorities
such as FDA and EMA. Consequently, extractables and leachables studies are now a crucial component of product release.

This conference will provide a wide and comprehensive overview of critical aspects, technical considerations and strategies for establishing an extractables study design that provides meaningful data, including the advantages and disadvantages of various analytical techniques for the pharmaceutical and medical device industry. The normative approach according to USP, ISO 10993-1 and
ISO/DIS 10993-18) will be discussed in detail.

By attending, participants will gain valuable insight from our first class expert’s comprehensive expertise on how to conduct risk assessment and toxicological evaluation recommending testing options that are up to current industry and regulatory standards and expectations.

This course offers a rewarding experience and is particularly relevant to the following key figures:
R&D Manager, CQ Manager, QA Manager, Regulatory Manager, Production Manager, Packaging Manager, CMC manager
and Validation Manager.

9:00 - 9:30: Registration

9:30 - 10:00: Introduction and general overview:
                    • Extractables and leachables definition
                    • The difference between extractables and leachables
                    • Guidelines regulatory requirements (USP<1663> <1664>; ISO 10993-1; ISO/DIS 10993-18)
                     Simone Carrara; Chiara Picotti

10:00 - 11:15: Extractables studies:
                      • When and how to set up an extractable study
                      • Critical evaluation of the packaging system, process components and drug properties (Risk Based Approach)
                      • Setting up an extractables study (Design of Experiment):
                        - Selection of extraction conditions
                        - Selection of extractive solvents
                        - Selection of extractive techniques (HS/GC/MS-GC/MS HPLC/MS/UV-ICP/OES-ICP/MS-Ion Chromatography)
                        - Definition of screening methods and minimum sensitivity request
                      • Specific case study
                       Simone Carrara

11:15 - 11:30: Coffee break

11:30 - 12:30: Peculiar feature of extractables and leachables for medical devices
                       Chiara Picotti

12:30 - 13:00: BPOG
                       Simone Carrara

14:00 - 15:45: Toxicological evaluation: Integrated approach:
                       • Maximum Daily Intake (MDI)
                       • Threshold of Toxicological Concern (TTC)
                       • Different approaches to the interpretation of data of known and unknown compounds
                       • Tolerable Intake (TI)/Tolerable Exposure (TE)
                       • NOAEL-LOAEL: Definition and selection criteria
                       • Uncertainty factors
                       • In silico predictions
                       • Cramer scheme, ToxTree Benigni/Bossa
                       • Specific case study
                        Chiara Picotti

15:45 - 16:00: Coffee break

16:00 - 16:30: Leachables studies:
                      • When and how to set up a leachablee study
                      • The approach on known and unknown extractables
                      • Targeted & non-targeted leachable screening
                      • Method development and validation
                      • Leachables studies stability plan
                      • Specific case study
                       Simone Carrara

16:30 - 17:15: Final case study step by step (prefilled syringe and administration set):
                      • Extractables studies
                      • Toxicological approach
                      • Leachables studies
                       Simone Carrara; Chiara Picotti

17:15 - 17:30 Final questions and answers

Chiara Picotti
With a degree in Biomedical Engineering she gained strong experience in the biological evaluation of medical devices field as senior consultant and Toxicological and Biological Evaluation Group Leader in Eurofins Medical Device Testing Italy. She manages a dedicated team for the calculation of the Permitted Daily Exposure in shared Facility and toxicological evaluations of extractables & leachables studies on medical devices, pharmaceutical packaging and process components.

Simone Carrara
Simone holds a Biotechnology degree from the University of Milan and has a vast experience as bio-analytical researcher through LC/MS method development for Pharmacokinetics analysis and ADMET profiling. In his previous role as Project Leader he has successfully managed different projects in a wide range of areas including analytical method development and validation with LC/MS-GC/MS, and drug product impurities characterization. For the last 5 years he has been focusing on extractables & leachables studies to support drug-manufacturing companies to fulfill regulatory requirements. He is currently Extractables & Leachables and impurity characterization
Laboratory Manager in Eurofins BioPharma Product Testing Italy.

Eurofins BPT & MDT Italy
Via Bruno Buozzi, 2
20090 - Vimodrone (Italy)
e-mail: FormazioneFarma@eurofins.com
website: www.eurofins.com/Medical-Device
website: www.eurofins.com/BPT

Edu-Med
9 Hagilad St. Ramat Gan
P.O Box 11530, ISRAEL
e-mail: office@edu-med.info